The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients

Phase 4

Completed

• Conditions: Hypertension; Essential; Uncomplicated Hypertension

• Registration Number: NCT00338338
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers). This study is to compare the efficacy and safety of Lacidipine with Amlodipine, the most widely used CCB in Taiwan, in hypertensive patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11-07
• Study First Submitted: 2006-06-16
• Study First Submitted QC: 2006-06-16
• Study First Posted: 2006-06-20
• Primary Completion: 2007-09-14
• Study Completion: 2007-09-14
• Status Verified: 2017-10
• Last Update Submitted: 2017-10-05
• Last Update Posted: 2017-10-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

• Informed consent written prior to the recruit into the study
• Male or female subjects
• Patients with diagnosis of essential, uncomplicated hypertension
• After one to two weeks washout period, patients showing, systolic blood pressure equal or lager than 160mmHg or diastolic blood pressure equal or lager than 90mmHg

Subject could be enrolled in one of the following state:

1. Patients previously untreated for hypertension;
2. Intolerant or not responding to their current therapy;
3. Patients controlled under their previous therapy but who can safely and agree to be switched to the trial therapy could clinically feasible for mono-therapy for hypertension control.

Read More

Exclusion Criteria

• Any form of secondary hypertension
• History of malignant hypertension or evidence of accelerated hypertension
• Myocardial infarction within 3 months
• Unstable angina pectoris
• Congestive heart failure
• Atrial fibrillation
• Life threatening arrhythmia
• History of cerebrovascular accident
• Clinically relevant renal disease; defines if serum creatinine equal or lager than 1.5 mg/dl
• Liver function abnormal: glutamic-oxalacetic transaminase lager than 2 times of upper limit normal or glutamic-pyruvic transaminase lager than 2 times of upper limit normal
• Existence of any serious systemic disease
• Allergic history to the compounds of both study medication
• Can not comply the study protocol or misunderstand the informed consent form
• Other diseases which treated by calcium channel blockers

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To evaluate the efficacy of of Lacidipine 4 or 6 mg and Amlodipine 5 or 10 mg on blood pressure profiles, in terms of blood pressure, heart rate, and edema after 8 weeks of treatment.

Secondary Outcome Measures

Name	Time	Method
To compare the overall safety profile of Lacidipine and Amlodipine, in terms of percentage and types of adverse events reported after 8 weeks of treatment.

Trial Locations

Locations (1)

GSK Investigational Site; 🇨🇳 Taipei, Taiwan